Tuesday, August 16, 2011
Rush researchers discover antibody that may help detect ovarian cancer in earliest stages - press release (mesothelin antibodies)
Note: in research
".....In the study at Rush, researchers tested for mesothelin antibodies in the bloodstream of 109 women who were infertile, 28 women diagnosed with ovarian cancer, 24 women with benign ovarian tumors or cysts, and 152 healthy women. Infertility was due to endometriosis, ovulatory dysfunction or premature ovarian failure or was unexplained.
Significant levels of mesothelin antibodies were found in women with premature ovarian failure, ovulatory dysfunction and unexplained infertility, as well as in women with ovarian cancer, although not in women with endometriosis and not in healthy women or women with benign disease. Endometriosis is generally associated with a different kind of ovarian carcinoma (blogger's note - cell types: endometrioid/clear cell) than other types of infertility, which may explain why mesothelin antibodies were not found in these cases.
Why the presence of mesothelin antibodies in the bloodstream should be linked with ovarian cancer is not clear.
"It has been hypothesized that an autoimmune response precedes or somehow contributes to the development and progression of malignant tumors," Luborsky said. "We think that antibodies may arise in response to very early abnormal changes in ovarian tissue that may or may not progress to malignancy, depending on additional triggering events. Or, alternatively, antibodies may bind to normal cells in the ovary, causing dysfunction and leading to infertility -- and, in a subpopulation of women, to the development of ovarian cancer.".....cont'd
free full access (pdf file) Cell - Hallmarks of Cancer: The Next Generation (published Mar 2011)
Hallmarks of Cancer: The Next Generation
Permissions
Cell, Volume 144, Issue 5, 646-674, 4 March 2011
Copyright © 2011 Elsevier Inc. All rights reserved.
10.1016/j.cell.2011.02.013
Copyright © 2011 Elsevier Inc. All rights reserved.
10.1016/j.cell.2011.02.013
Authors
Summary
The hallmarks of cancer comprise six biological capabilities acquired during the multistep development of human tumors. The hallmarks constitute an organizing principle for rationalizing the complexities of neoplastic disease. They include sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis. Underlying these hallmarks are genome instability, which generates the genetic diversity that expedites their acquisition, and inflammation, which fosters multiple hallmark functions. Conceptual progress in the last decade has added two emerging hallmarks of potential generality to this list—reprogramming of energy metabolism and evading immune destruction. In addition to cancer cells, tumors exhibit another dimension of complexity: they contain a repertoire of recruited, ostensibly normal cells that contribute to the acquisition of hallmark traits by creating the “tumor microenvironment.” Recognition of the widespread applicability of these concepts will increasingly affect the development of new means to treat human cancerfull free text: (pdf file) Cell - A ceRNA Hypothesis: The Rosetta Stone of a Hidden RNA Language?
A ceRNA Hypothesis: The Rosetta Stone of a Hidden RNA Language?
- Main Text
- The Noncoding Revolution
- The ceRNA Protagonists
- MicroRNAs
- The Transcriptome
- The ceRNA Hypothesis
- RNA Transcripts Communicate through the ceRNA Language
- Logic and Regulation of the ceRNA Network
- Experimental Evidence Supporting the ceRNA Hypothesis
- ceRNAs in the Etiology of Cancer
- Conclusions
- Acknowledgments
full free access: ScienceDirect - Cell : The Hallmarks of Cancer published Sept 2000
 |  |
 doi:10.1016/S0092-8674(00)81683-9 | How to Cite or Link Using DOI | |
| Permissions & Reprints |
Review
The Hallmarks of Cancer
Douglas Hanahan 1 and Robert A. Weinberg 2Available online 27 September 2000.
Article Outline
Subscribe to:
Posts
(
Atom
)
Posts
